AI-Driven Clinical Trial Design & Optimization

Machine Learning & Full Stack (Team Eta)

Team Members:

Zarnab Zafar (Team Lead)

Ayesha Majeed

Muhammad Mustafa Shah

Wajahat Hussain

Dil Nawaz

Ali Khan

Muhammad Abu Bakar



Proof of Concept



Project or product name:

AI-Driven Clinical Trial Design and Optimization



The problem: -

The traditional design and execution of clinical trials are often inefficient, costly, and prone to high failure rates. Current methodologies are limited by their inflexibility, leading to delays in bringing new treatments to market. There is a pressing need for innovative approaches to optimize trial design, reduce costs, and increase success rates.



Target audience: _____

Pharmaceutical Companies: Interested in reducing the cost and time required for drug development.

Clinical Research Organizations (CROs): Focused on improving trial design and execution.

Regulatory Bodies: Involved in ensuring the safety and efficacy of new treatments.

Healthcare Providers: Seeking more efficient and effective ways to bring new therapies to patients.

AI and Data Science Teams: Interested in applying AI-driven models to real-world problems in healthcare.

🌅 Resources needed:

Data: Access to historical clinical trial data from sources like ClinicalTrials.gov, PubMed, and Proprietary pharmaceutical datasets.

Software Tools: Machine learning frameworks (e.g., TensorFlow, PyTorch), Data preprocessing tools, Visualization platforms.

Expertise:

- Data scientists
- Ai/ml engineers
- Clinical trail expert
- Full stack developers
- Domain expert in pharmacology

Success criteria/KPIs:-

To determine whether the POC has passed, the following metrics will be used:

Efficiency Gain: Faster clinical trial design and execution.

Cost Reduction: Decrease in overall trial costs through optimized design and participant recruitment.

Predictive Accuracy: Accuracy of AI models in predicting trial outcomes based on historical data.



Project scope:

Data Collection and Integration: Compile and preprocess data from various sources to create a unified database.

AI Model Development: Develop predictive and adaptive models for trial design and recruitment.

Platform Development: Create a user interface for researchers to input trial parameters and receive AI-driven recommendations.

Phase 1:	Date range: 3 days
Data Collection and pre-processing.	
Phase 2: AI Model Development.	Date range: 3 days
Phase 3:	Date range: 3 days
Platform Development.	

Conclusion:

This project aims to transform the clinical trial design process through the application of AI-driven models and tools. By optimizing trial designs, improving participant recruitment, and enabling adaptive methodologies, this project has the potential to significantly reduce the time and cost associated with clinical trials while increasing their success rates. The development of an AI-driven platform for clinical trial design and optimization could lead to more efficient drug development, faster access to new therapies, and ultimately better healthcare outcomes.



POC Results Analysis:

The POC successfully demonstrated the use of AI models to optimize clinical trial design. The Random Forest model achieved 98% accuracy, making it the most effective model for predicting clinical trial outcomes. The model was validated using cross-validation and ROC curve analysis, confirming its reliability. The POC also highlighted the importance of feature selection and data preprocessing in achieving high predictive accuracy.

